Clinical Trial Update: Busulfan, Fludarabine Phosphate, and Anti-Thymocyte Globulin Followed By Donor Stem Cell Transplant and Azacitidine in Treating Patients With High-Risk Myelodysplastic Syndrome and Older Patients With Acute Myeloid Leukemia [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating a conditioning regimen of busulfan, fludarabine phosphate, and anti-thymocyte globulin followed by donor stem cell transplant and azaci…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndromes

Drugs mentioned

• AZACITIDINE (AZACITIDINE)
• BUSULFAN (Busulfan)
• Fludarabine phosphate (Fludarabine phosphate)
• anti-thymocyte globulin (antithymocyte globulin)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Acute Myeloid Leukemia, Adult Acute Megakaryoblastic Leukemia | Phase 2 | Status: COMPLETED | Results posted: 2018-04-03